NeOnc Technologies Holdings Reports Q2 GAAP EPS of $0.30, with Increased G&A and R&D Expenses.

NeOnc Technologies Holdings reported Q2 GAAP EPS of $0.30, with G&A expenses increasing to $984K from $290K in Q2 2024 due to expanded marketing, rent, travel, and Middle East partnership-related costs. R&D expenses rose to $677K from $394K in Q2 2024, driven by additional trial sites, increased recruitment for NEO212, and initiation of NEO100-3.

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biotechnology company specializing in central nervous system (CNS) cancer therapies, released its second-quarter (Q2) 2025 financial results on August 19, 2025. The company reported a GAAP EPS of $0.30, with significant increases in general and administrative (G&A) expenses and research and development (R&D) costs.

G&A expenses for Q2 2025 totaled $984K, up from $290K in Q2 2024, primarily due to expanded marketing efforts, rent, travel, and costs related to a strategic partnership with Quazar Investment in the Middle East [1]. R&D expenses rose to $677K from $394K in Q2 2024, driven by additional trial sites, increased recruitment for NEO212, and the initiation of NEO100-3, a pediatric indication trial [1].

The company's net loss for Q2 2025 was $5.68M, compared to $4.52M in Q2 2024. This increase was largely due to the absence of prior-year financing-related and stock-based compensation expenses [1].

NeOnc Technologies also announced several operational highlights and upcoming milestones. The company secured a $50 million strategic partnership with Quazar Investment, which will launch an advanced clinical trials platform in the GCC and MENA regions. Additionally, NeOnc was awarded $2.5 million in STTR grants to advance NEO212 for gliomas and leukemia [1].

The company signed a definitive agreement to acquire an intellectual property (IP) portfolio from Dr. Ishwar K. Puri, including AI, 3D bioprinting, and quantum modeling technologies. NeOnc also entered a 12-part national TV and media campaign with New to The Street, increasing its market visibility [1].

Executive Chairman Amir Heshmatpour commented on the quarter's results, stating, "This has been a transformative period for NeOnc. Meeting all the outstanding contingencies for our $50 million strategic partnership with Quazar Investment, being added to the Russell Microcap Index, advancing multiple clinical programs, and acquiring cutting-edge AI and quantum modeling capabilities position us for accelerated growth" [1].

Upcoming catalysts include the completion of NEO100-01 Phase 2a enrollment by September 2025, completion of NEO212 Phase I final cohort dosing in 2025, and NEO100-01 top-line data readout in early 2026 [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9514368/neonc-technologies-holdings-reports-second-quarter-2025-results-and-provides-operational-update